- Home
- KPLT vs RLYB Comparison
KPLT vs RLYB Comparison
Compare KPLT & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPLT
- RLYB
- Stock Information
- Founded
- KPLT 2012
- RLYB 2018
- Country
- KPLT United States
- RLYB United States
- Employees
- KPLT N/A
- RLYB N/A
- Industry
- KPLT Diversified Commercial Services
- RLYB Biotechnology: Pharmaceutical Preparations
- Sector
- KPLT Consumer Discretionary
- RLYB Health Care
- Exchange
- KPLT Nasdaq
- RLYB Nasdaq
- Market Cap
- KPLT 34.5M
- RLYB 14.4M
- IPO Year
- KPLT N/A
- RLYB 2021
- Fundamental
- Price
- KPLT $9.58
- RLYB $0.41
- Analyst Decision
- KPLT Hold
- RLYB Hold
- Analyst Count
- KPLT 2
- RLYB 3
- Target Price
- KPLT $12.00
- RLYB $15.00
- AVG Volume (30 Days)
- KPLT 26.1K
- RLYB 8.1M
- Earning Date
- KPLT 08-13-2025
- RLYB 08-07-2025
- Dividend Yield
- KPLT N/A
- RLYB N/A
- EPS Growth
- KPLT N/A
- RLYB N/A
- EPS
- KPLT N/A
- RLYB N/A
- Revenue
- KPLT $254,079,000.00
- RLYB $848,000.00
- Revenue This Year
- KPLT $22.26
- RLYB N/A
- Revenue Next Year
- KPLT $11.03
- RLYB N/A
- P/E Ratio
- KPLT N/A
- RLYB N/A
- Revenue Growth
- KPLT 9.72
- RLYB N/A
- 52 Week Low
- KPLT $5.08
- RLYB $0.22
- 52 Week High
- KPLT $21.88
- RLYB $1.54
- Technical
- Relative Strength Index (RSI)
- KPLT 62.96
- RLYB 55.26
- Support Level
- KPLT $7.95
- RLYB $0.32
- Resistance Level
- KPLT $8.44
- RLYB $0.61
- Average True Range (ATR)
- KPLT 0.65
- RLYB 0.05
- MACD
- KPLT 0.09
- RLYB 0.01
- Stochastic Oscillator
- KPLT 99.56
- RLYB 34.82
About KPLT Katapult Holdings Inc.
Katapult Holdings Inc. is a technology-driven lease-to-own platform that integrates with omni-channel retailers and e-commerce platforms to power the purchase of everyday durable goods for underserved U.S. non-prime consumers. It is an e-commerce-focused FinTech company offering a lease-purchase solution to consumers and enabling essential transactions at the merchant point of sale. Katapult is associated with hundreds of retailers across the United States.
About RLYB Rallybio Corporation
Rallybio Corp is a clinical stage biotechnology company committed to identifying and accelerating the development of life-transforming therapies for patients with severe and rare disorders. The programs of the company are for the prevention of fetal and neonatal alloimmune thrombocytopenia, a potentially life-threatening rare disease that can cause uncontrolled bleeding in fetuses and newborns.